BCMA CAR-T Clinical Data Actively Developed jointly by Cinda Bio and Reindeer Medical

CT103A is an anti-BCMA CAR-T cell injection developed jointly by Cinda Bio and Reindeer Medical to treat recurrent or refractory multiple myelomaAt the annual meetings of ASCO and EHA, CT103A showed positive data: the objective mitigation rate (ORR) was 100%, and CAR-T has a strong persistence and amplification ability in the body, which will hopefully provide a new treatment for patients with recurrent/incurable multiple myeloma (RRMM), especially patients who have received rat-derived single-chain antibody CAR-T treatment for relapsemultiple myeloma (MM) is a malignant blood system tumor with abnormal proliferation of cloning plasma cells that has not been medically curedMultiple myeloma is the second most common blood tumor in many countriesThe American Cancer Society estimates that there will be 32,110 new confirmed cases in the United States in 2019More than 48,200 patients in Europe were diagnosed with multiple myeloma in 2018, 40% of whom were patients with moderate- to high-risk multiple myeloma, with a survival time of no more than five yearsas of May 22, 2019, the objective remission rate (ORR) of the 11 assessable subjects treated with CT103A was 100% (7 CR, 4 VGPR) with a maximum follow-up time of 8 monthsCAR-T exhibits good amplification and durability in patientsAll patients were assessed for CRS, which occurred within 2-5 days (median: 2.6 days) and subsided within 14 daysThe majority of CRS in the low to medium dose group were 1 to 2, and the high-dose group observed higher levels of CRS, CRS conventionally treated with tobeads monoantigen and steroidsOf concern, the 11 assessable patients included 4 patients who had previously relapsed after treatment with rat-derived anti-BCMA CAR-T, including 3 with complete remission (CR) and 1 case of very good partial remission (VGPR)1: Clinical Data -- Clinical data graphshows show objective remission rate (ORR) of 100%, total remission (CR) 64%, and very good partial remission (VGPR) 36%Bold and underlined indicates that the patient relapsed after previousLY RECEIVING CAR-T treatment(Data as of: 05/22/2019)Figure 2: CT103A amplification and persistence -- amplification and persistence after CAR-T backlossThe color of the line indicates the patient's 14-day evaluation of efficacy; The dose is 1 (round), 3 (square), 6 (triangle) x 106 cells/kg; (Data as of: 05/22/2019)Figure 3: The occurrence of CYTOkine dysplint syndrome (CRS) in CRSAll 12 patients were assessed for CRSIn all cases, CRS was relieved within 14 days of intervention and non-intervention
note: